CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...
CSPC Pharmaceutical
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has revealed that it has obtained an Emergency...
CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...
CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...
CSPC’s Octreotide Long-Acting Injection Approved for Acromegaly Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval...
CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...
CSPC Pharmaceutical Reports Q3 2022 Financials with 13.8% Revenue Growth
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its Q3 2022 financial results, reporting...
Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...
CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for...
CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
CSPC Receives CDE Approval for Generic Version of Pfizer’s Xeljanz
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received market...
CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...
Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...